These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8962193)

  • 1. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation.
    Silva HT; Cao W; Shorthouse R; Morris RE
    Transplant Proc; 1996 Dec; 28(6):3082-4. PubMed ID: 8962193
    [No Abstract]   [Full Text] [Related]  

  • 2. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
    Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis.
    Silva HT; Cao W; Shorthouse RA; Löffler M; Morris RE
    Transplant Proc; 1997; 29(1-2):1292-3. PubMed ID: 9123312
    [No Abstract]   [Full Text] [Related]  

  • 4. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.
    Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E
    Transplant Proc; 1996 Dec; 28(6):3088-91. PubMed ID: 8962196
    [No Abstract]   [Full Text] [Related]  

  • 5. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection.
    Savikko J; Von Willebrand E; Häyry P
    Transplantation; 2003 Aug; 76(3):455-8; discussion 471-3. PubMed ID: 12923428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of leflunomide in rheumatoid arthritis.
    Fox RI
    J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine.
    Fukushima R; Kanamori S; Hirashiba M; Hishikawa A; Muranaka R; Kaneto M; Kitagawa H
    Toxicol Sci; 2009 Apr; 108(2):419-26. PubMed ID: 19190124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
    Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
    J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PDGF-stimulated rat smooth muscle cell proliferation by MNA 279 and MNA 715.
    Czech J; Schwab W; Schorlemmer HU
    Transplant Proc; 1998 Dec; 30(8):4197-9. PubMed ID: 9865347
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
    Greene S; Watanabe K; Braatz-Trulson J; Lou L
    Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression.
    Chong AS; Gebel H; Finnegan A; Petraitis EE; Jiang XL; Sankary HN; Foster P; Williams JW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):747-9. PubMed ID: 8438466
    [No Abstract]   [Full Text] [Related]  

  • 12. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.
    Cherwinski HM; McCarley D; Schatzman R; Devens B; Ransom JT
    J Pharmacol Exp Ther; 1995 Jan; 272(1):460-8. PubMed ID: 7529314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
    Korn T; Magnus T; Toyka K; Jung S
    J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats.
    Silva HT; Shorthouse R; Morris RE
    Transplant Proc; 1996 Dec; 28(6):3092-4. PubMed ID: 8962197
    [No Abstract]   [Full Text] [Related]  

  • 15. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
    Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
    Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
    Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR
    Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats.
    Gregory CR; Silva HT; Patz JD; Morris RE
    Transplant Proc; 1998 Jun; 30(4):1047-8. PubMed ID: 9636423
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
    Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
    J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FK778: new cellular and molecular mechanisms of action.
    Schrepfer S; Deuse T; Koch-Nolte F; Detter C; Reichenspurner H
    Transplant Proc; 2006 Apr; 38(3):757-61. PubMed ID: 16647464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations.
    Papageorgiou C; Albert R; Floersheim P; Lemaire M; Bitch F; Weber HP; Andersen E; Hungerford V; Schreier MH
    J Med Chem; 1998 Aug; 41(18):3530-8. PubMed ID: 9719606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.